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Wound dressings are a mainstay of treatment; being applied to a wound
as part of a wider treatment strategy, guidelines include compression,
debridement, offloading and infection control to achieve full wound
closure 1,2.
Protease-modulating-matrix (PMM) dressings have an effect on the
matrix-metalloproteases (MMPs) that are present in chronic wounds.
These interventions are intended to rebalance the levels of MMPs in the
wound bed, stimulating healing and improving outcomes.
Wound dressings
To determine if protease modulating treatments are a clinically effective treatment strategy for Diabetic Foot Ulcers or Leg Ulcers.
This study found evidence of protease-modulating interventions being clinically effective in the management of DFU and VLU. Two studies compare
two wound care products by the same manufacturer, achieving double-blinding by producing both the intervention and control dressing with the
same material, packaging and colours as one another; with the sole difference being the addition of the PMM agent 5, 7.
The critical review of the evidence scored the RCTs as being of an overall moderate quality. The observational studies both scored as being of poor
quality. This uncertainty of evidence means that more work is required to produce further evidence. Expert opinion in conjunction with data from
clinical studies and literature could inform better treatment practices.
This systematic review highlights the need for further research into the efficacy of protease-modulating treatments. They have been shown to have
some efficacy; with the dressing preparation being particularly beneficial to ulcers that are older and larger; which are often the most burdensome
ulcers.
The findings of this systematic review could be used to inform clinical decision making with regards to PMM interventions. These interventions are
more costly than basic alternatives; however this review has shown that they may improve healing outcomes for to patients; with enhanced
potential in patients with DFU and on older and larger wounds.
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Objective
Methods Results
Conclusions
Advice from the National Institute for Health and Care Excellence (NICE)
recommends “the least costly dressing of the type that meets the
required characteristics appropriate for the type of wound” 3.
A prior systematic review of PMM dressings did not find conclusive
evidence of clinical benefit for Venous Leg Ulcers4. However newer
studies have now been published; a pooled analysis5 and a Double-Blind
Randomised Clinical Trial6 showing superior outcomes for PMM
dressings. This has highlighted the need for a review of the evidence.
Uncertainty and new evidence
From searching the databases 272 results were returned.
Discussion with Experts and Manufacturers provided 11 further
titles. After initial screening of the 283 titles and abstracts, 68 were
excluded for being irrelevant. The remaining 215 texts were judged
against the inclusion and exclusion criteria. 202 titles were
excluded, with 8 being included as per the PRISMA flow chart.
Of the studies included, 3 had a primary outcome of relative WAR
and 5 assessed healing or closure outcomes. Edmonds 2018
demonstrates an odds ratio of 2.6 (p=0.002) of healing at 20 weeks
when using a PMM dressing on a DFU 5. Looking at the total
population Munter shows a 30.8% benefit when a treatment
regime included the Protease Modulating Dressing, presenting as a
29.8% (CI: 28.8%-30.9%) benefit for LU patients and 37.4% (CI:
34.8%-40.1%) for DFUs 6.
Inclusion criteria
Population Diabetic Foot Ulcer, Venous Leg Ulcer
Interventions Protease Matrix Modulating dressings and topical
applications
Outcomes Wound Area Reduction (WAR), Wound Closure,
Study design Randomised Controlled Trials, Observational studies
Language English Language
Search dates Search was carried out December 2017, date unrestricted.
Exclusion criteria
Population Paediatrics (<18), Acute wounds
Interventions Surgical. Novel-non-surgical. Infection control. Debridement.
Bioengineered skin substitute. Offloading. Prevention.
Outcomes Not meeting inclusion criteria
Study design In vitro studies, review or discussion articles, Treatment
pathway/guidelines, Systematic/ Literature Reviews or Meta
analyses, Epidemiology Studies, Modelling, Case Studies,
Economic studies, Database Studies
Language Non-English language
Search dates Unrestricted
A systematic review following the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines
was undertaken. This included a database search, and consultation with
experts and manufacturers to identify additional literature.
Databases searched: Centre Reviews and Dissemination (CRD) York
Database, Cochrane Library, Medline (PubMed), National Institute for
Health and Clinical Excellence Evidence Search, Science Direct/Scopus.
Two researchers performed data extraction with a third consulted in
case of discrepancies. A narrative synthesis of results and critical
appraisal of included studies as per the NICE submission template for
Medical Technologies Evaluation Programme; which has been derived
from the Centre for Reviews and Dissemination (CRD) was performed.
Table 1. Inclusion/Exclusion Criteria
Figure 1. PRISMA flow diagram
